Cohen, Taylor S.
Kelly, Elizabeth J.
Nylander, Sven
Bansal, Himanshu
Jepson, Brett M.
Bhuyan, Prakash
Sobieszczyk, Magdalena E.
Falsey, Ann R.
Funding for this research was provided by:
AstraZeneca
US Government (Agreement No. W15QKN-20-9-1003)
Article History
Received: 14 January 2022
Accepted: 27 April 2022
First Online: 13 May 2022
Competing interests
: The authors declare no competing non-financial interests but the following competing financial interests. TSC, EJK, SN, HB, BJ, and PB are employees of AstraZeneca. TSC, EJK, and SN hold or may hold stock in AstraZeneca. MES receives NIH/NIAID funding for trials of COVID-19 vaccines and for HIV/AIDS Clinical Trials Unit (CTU) (2UM1AI069470), as well as research grants from the Gates Foundation, Sanofi, Janssen, Merck, and Gilead to her institution. ARF receives research grants from Pfizer, Janssen, and Merck Sharpe and Dohme, and is a member of the Data Safety Monitoring Board for Novavax.